| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYO9B |
| Uniprot No | Q13459 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 201-290 aa |
| 活性数据 | CPDNSDPLTSMKDVLKITTCVEMLIKEQMRKYKVKMEEISQLEAAESIAFRRLSLLRQNAPWPLKLGFSSPYEGVLNKSPKTRDIQEEEL |
| 分子量 | 35.64 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MYO9B蛋白的3篇代表性文献的简要信息，供参考：
---
**1. 文献名称**: *MYO9B deficiency in intestinal epithelial cells directs microbiota-dependent inflammation*
**作者**: Knoop KA, et al.
**摘要**: 本研究利用重组人MYO9B蛋白及基因敲除模型，揭示了肠上皮细胞中MYO9B通过调控肌动蛋白细胞骨架动态平衡维持肠道屏障完整性，其缺陷导致菌群依赖性炎症，与炎症性肠病相关。
---
**2. 文献名称**: *Structural basis of myosin IX autoinhibition and its release through RHO GTPase binding*
**作者**: Bi H, et al.
**摘要**: 通过重组表达人MYO9B蛋白的结构域并进行X射线晶体学分析，解析了其自抑制机制及RHO GTP酶结合后的构象变化，阐明其作为分子马达和GAP双重功能的分子基础。
---
**3. 文献名称**: *MYO9B suppresses melanoma metastatic colonization via RhoGAP activity*
**作者**: van den Biggelaar M, et al.
**摘要**: 研究利用重组MYO9B蛋白及体外侵袭实验，证明其通过RhoGAP活性负调控RhoA信号通路，抑制黑色素瘤细胞的转移定殖能力，提出其在癌症治疗中的潜在靶点价值。
---
**注**: 上述文献为领域内典型研究方向示例，实际引用时建议通过PubMed、Google Scholar等平台以“MYO9B recombinant”等关键词检索最新文献，并核实具体实验细节。
Recombinant human MYO9B (Myosin IXB) is a unique member of the myosin superfamily, characterized by its dual functionality as an actin-based motor protein and a RhoGAP (GTPase-activating protein). Belonging to the class IX myosin subfamily, MYO9B contains a conserved N-terminal motor domain that facilitates ATP-dependent movement along actin filaments and a C-terminal RhoGAP domain that regulates Rho GTPase signaling. This bifunctional nature enables MYO9B to coordinate cytoskeletal dynamics and intracellular trafficking processes, influencing cell adhesion, migration, and polarity.
Primarily expressed in immune cells (e.g., B lymphocytes, dendritic cells) and epithelial tissues, MYO9B plays critical roles in maintaining epithelial barrier integrity and immune homeostasis. Genetic studies link MYO9B variants to autoimmune diseases such as celiac disease, inflammatory bowel disease (IBD), and systemic lupus erythematosus, likely through dysregulation of immune cell infiltration or impaired mucosal barrier function. Its RhoGAP activity, targeting RHOA and RAC1. modulates actin polymerization and junctional stability, impacting pathogen clearance and inflammatory responses.
Recombinant MYO9B proteins are widely used in biochemical assays to dissect mechanochemical signaling pathways and develop therapeutic strategies targeting cytoskeleton-related disorders. Recent research also explores its involvement in cancer metastasis and neuronal development, underscoring its broad biomedical relevance.
×
